29 Examiners Available Now — Contact Them DirectlyNo Booking Fee — You Pay Your Examiner Directly270+ Testing Locations Across the U.S., Canada & UKFree Polygraph Research Database — 44,000+ StudiesWe Promote Clear Standards & Best Practice in Private Polygraph TestingLearning Center — Independent Guides to Every Type of Polygraph TestSame-Day Verbal Result · Written Report Within 48 HoursVetted Examiners Trained at Accredited Polygraph Schools100% Confidential — Private, Appointment-Only TestingPolygraph Glossary (600+ Terms), Book Library & School DirectoryTrusted by 10,000+ Clients, Attorneys & Organizations
LieDetectorTest.com Stop guessing. Get the truth.
Research ledger
Meprobamate reduces the accuracy of physiological detection of deception

Home › Polygraph Research › Meprobamate reduces the accuracy of physiological detection of…

Catalogue entry · Countermeasures Research

Meprobamate reduces the accuracy of physiological detection of deception

Martin Theodore Orne — Science,

1981Published
44 male college students (33 guilty, 11 innocent)Sample size
Key findings

A standard 400 mg clinical dose of meprobamate rendered the electrodermal-based Guilty Knowledge Test unable to reliably distinguish deceptive from truthful subjects, while the examiner was unable to detect drug use from behavioral observation alone.

Abstract

This 1981 study by Waid, Orne, Cook, and Orne, published in Science, conducted a double-blind laboratory experiment to test whether meprobamate — a common tranquilizer — could impair the accuracy of polygraph-based deception detection using the Guilty Knowledge Test. The study found that deceptive subjects who ingested 400 mg of meprobamate were misclassified as truthful at rates indistinguishable from innocent subjects, while the examiner could not identify which subjects had taken the drug.

Methodology

A randomized, double-blind laboratory experiment with 44 male college students assigned to guilty (meprobamate, placebo, or no-pill) and innocent conditions, using the Guilty Knowledge Test with electrodermal, respiratory, and cardiovascular recording.

Detailed summary

This groundbreaking 1981 study challenged the assumption that tranquilizers would only produce general arousal reduction without affecting deception detection. Using a rigorous double-blind design, researchers administered 400mg of meprobamate to guilty subjects before polygraph testing with the Guilty Knowledge Test. The results demonstrated that meprobamate selectively reduced physiological responses to deception-relevant items rather than producing uniform response suppression. This finding revealed that antianxiety medications could serve as effective pharmacological countermeasures, fundamentally undermining the polygraph's detection capability by targeting the very physiological signals the test depends upon.

Implications for polygraph practice

The findings demonstrated that commonly available tranquilizers could serve as effective countermeasures against polygraph detection, raising serious concerns about the vulnerability of polygraph testing to pharmacological manipulation in real-world applications.

Comprehensive study analysis

An in-depth, original analysis of this research study's methodology, findings, and significance for the polygraph profession.

Background & Context

By the late 1970s and early 1980s, the polygraph had become deeply embedded in criminal investigation and personnel screening across the United States, yet the scientific community remained sharply divided over its validity. Professional polygraphers had long assumed that tranquilizers might reduce physiological responses to all test questions as part of a general reduction in tonic arousal, but that the critical difference in reactivity between deception-related and control items would remain unaffected. This was a foundational assumption that had never been rigorously tested.

Clinical and pharmacological perspectives on tranquilizers, however, suggested otherwise — that a tranquilizer's primary effect might be precisely to reduce the physiological correlates of fear or anxiety tied to the critical questions themselves. If that was true, tranquilizing drugs could act as a selective pharmacological countermeasure, neutralizing the very physiological signal that polygraph detection depends upon.

Empirical evidence for either view was sparse. While antianxiety drugs had been shown to reduce the electrodermal response to certain stressful stimuli — such as anticipation of electric shock, emotionally charged words, or carnival rides — their effects on the electrodermal response to natural social stressors such as interpersonal conflict had not been investigated. This study by Waid, Orne, Cook, and Orne filled that critical empirical gap with a rigorous, double-blind experimental design.

Research Design & Methodology

The researchers conducted a double-blind test of the effects of meprobamate — a widely used minor tranquilizer — on polygraph test results. The study employed the Guilty Knowledge Test (GKT), also known as the concealed information technique, which assesses whether a subject shows differential physiological responses to crime-relevant items embedded among neutral foils.

Key design elements included:

  • Participants: Male college students aged 18 to 24, recruited through advertisements and paid $2 per hour. The research team was William M. Waid, Emily Carota Orne, Mary R. Cook, and Martin T. Orne.
  • Groups: Subjects were randomly assigned to guilty (N = 33) or innocent (N = 11) conditions. Guilty subjects were further subdivided into three groups: 400 mg meprobamate (N = 11), placebo (N = 11), and no pill (N = 11).
  • Drug administration: Meprobamate taken orally reaches its peak plasma concentration in 1 to 2 hours, and subjects were tested 30 minutes after ingestion to capture the drug's onset window.
  • Test stimuli: A question list of 24 words across six semantic categories was presented twice, with guilty subjects lying 12 times in total.
  • Physiological channels: Subjects were recorded on electrodermal, respiratory, and cardiovascular activity.
  • Classification criterion: A conservative threshold of five or more items with responses indicative of deception was required for a "deception indicated" verdict.

Critically, the examiner administering the test was blind to each subject's group assignment. A separate experimenter subsequently rated whether each subject appeared to have taken a tranquilizer, enabling an assessment of whether drug use could be detected behaviorally — a key practical question for field examiners.

Results & Key Findings

The central finding was striking: meprobamate effectively neutralized the polygraph's ability to detect deception. The electrodermal response (EDR) identified most guilty subjects in the no-pill and placebo groups, with differences between those groups and the innocent group statistically significant at P < .005. Most meprobamate subjects, however, were mistakenly classified as truthful, and the discrimination between the meprobamate group and the innocent group was not statistically significant.

  • No-pill group: Deceptive subjects detected at statistically significant rates (P < .005 vs. innocent)
  • Placebo group: Deceptive subjects detected at statistically significant rates (P < .005 vs. innocent)
  • Meprobamate group: Most deceptive subjects classified as truthful — discrimination from innocent group was not statistically significant
  • Meprobamate vs. no-pill: Significant difference at P < .01
  • Meprobamate vs. placebo: Significant difference at P < .04
  • Examiner detection of drug use: Did not approach statistical significance — examiners could not identify which subjects had taken the tranquilizer

An important nuance emerged regarding the mechanism. The drug did not simply suppress all electrodermal activity uniformly. There were no differences among the four groups in the mean number of critical words that evoked a measurable EDR — all subjects continued to respond electrodermally throughout the test. However, drug subjects did not respond more strongly when lying than when telling the truth, whereas the guilty no-pill and placebo subjects did. This confirmed the clinical hypothesis: meprobamate selectively dampened the anxiety-driven differential response rather than abolishing physiological responding altogether.

Additionally, those who had ingested a placebo or nothing were detected with statistically significant frequency based on their phasic electrodermal responses, which clearly distinguished them from truthful suspects — but that was not the case with deceptive subjects who had ingested 400 milligrams of meprobamate. Respiratory and cardiovascular measures failed to discriminate between guilty and innocent subjects in any group, consistent with the broader literature on the EDR's superior utility in concealed information testing.

Discussion & Significance

These results carry profound implications for how polygraph validity is understood. The findings directly challenged the widely held view among polygraph examiners that tranquilizers might depress electrodermal responses uniformly but would not reduce the difference between responses that leads to detection — and also the view that tranquilized subjects can be recognized by an experienced examiner. Both assumptions, which had shaped professional polygraph practice for decades, were empirically refuted in a single well-controlled experiment.

The results indicated that such drugs may pose a serious threat to the detection of deception by means of the polygraph. Especially alarming is the combination of two findings: first, that 400 mg of meprobamate — a standard minimum clinical dose — was sufficient to defeat detection; and second, that the examiner could not reliably identify which subjects had taken the drug. This means the countermeasure is both effective and covert.

The authors were careful to note important boundary conditions. They acknowledged that field polygraph settings, with their higher stakes and more intrusive questioning, might generate enough anxiety to overcome the drug's effects. They also noted that higher doses (up to 800 mg) could be administered without producing observable behavioral impairment, potentially making the countermeasure even more robust. These considerations underscore that the study raises urgent questions rather than closing them.

Limitations & Considerations

The authors themselves identified several important caveats, which should be weighed carefully when interpreting these findings:

  • Laboratory vs. field generalizability: The experimental setting involved lower stakes than a real criminal investigation; genuine fear of detection in a field polygraph might overcome the drug's effects.
  • Test format: The study used the Guilty Knowledge Test (GKT). The authors noted it may be uncertain whether findings generalize to the Control Question Test (CQT), the format most commonly used in field settings.
  • Sample characteristics: All participants were young male college students — a narrow demographic that limits generalizability to broader populations, including women and older adults.
  • Drug timing: The polygraph was administered before meprobamate reached its peak plasma concentration (1–2 hours), meaning the full effect of the drug may not have been captured.
  • Single drug tested: Only meprobamate was examined; results cannot be assumed to extend to benzodiazepines, beta-blockers, or other common anxiolytics.
  • Sample size: With only 11 subjects per condition, the study had limited statistical power to detect smaller effects or subgroup differences.

Despite these constraints, the double-blind design, systematic use of three comparison groups, and replication of prior EDR detection findings in the no-drug and placebo conditions substantially strengthen confidence in the core result. The study's publication in Science — one of the world's most prestigious peer-reviewed journals — attests to the rigor of its methodology and the importance of its implications.

Practical Applications

For polygraph practitioners and security professionals, this research highlights a concrete vulnerability in psychophysiological deception detection: a commercially available, orally administered tranquilizer at a standard clinical dose can reliably impair test accuracy while remaining undetectable to the examiner. This has direct implications for pre-test protocols, particularly in high-stakes screening contexts where subjects are motivated to defeat the examination. Examiners cannot rely on behavioral observation alone to identify pharmacologically compromised tests.

For consumers, legal professionals, and policymakers, the study underscores why independent scientific scrutiny of polygraph limitations is essential. Psychophysiological detection of deception fundamentally depends upon the subject having larger physiological reactions to deception-related questions than to control questions — and any pharmacological agent that selectively attenuates those differential responses will systematically degrade accuracy without leaving a visible trace. This research remains a cornerstone reference in discussions of polygraph countermeasures, supporting calls for robust, multi-modal assessment protocols and caution in relying on polygraph results as standalone evidence.

Read the original study

The analysis above is original editorial content based on our review of this research. For the complete study including full data, methodology details, and author discussion, access the original publication below.

Related research

Other studies in this category that may be of interest.

Join Our Examiner Network

APA-trained examiners using validated techniques can apply to join the LieDetectorTest.com network.

Apply now →

Keep reading the ledger.

Every peer-reviewed study on polygraph and deception detection we track — catalogued, searchable and citable.

Need to book now? Our online booking system is open 24/7. Speak directly with our team about your test or booking.